Articles tagged with Metastasis
Researchers at Children's Hospital of Philadelphia define a 3-tiered molecular classification system for pediatric differentiated thyroid cancer, where fusion oncogenes are associated with more invasive disease and lower remission rates. The study contrasts findings from adults, who have a two-tiered system based on BRAF mutations.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
A new study by WVU researcher William Walker found that the blood-brain barrier is dynamic and more receptive to chemotherapy at night. This could lead to better treatment outcomes for patients with brain metastasis.
Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.
Melanoma cells release small packages containing the protein NGFR, which primes nearby lymph nodes to form new vessels and encourage cancer spread. This process, called lymphangiogenesis, may help doctors determine which patients need more aggressive treatment.
A new bilateral tumor model was demonstrated to be useful for investigating the relationship between T-cell repertoire and cancer immunotherapy's therapeutic effects. The study found that T-cell profiles of both tumors were almost identical, indicating a similar anti-tumor response in a single mouse.
A study investigated the common use of extended radiation therapy for patients with metastatic cancer nearing the end of life. Despite guidelines advising against this practice, researchers found that it is still used in many cases. The study aims to shed light on this treatment approach and its implications for patient care.
A study published in Cell Metabolism reveals unique features of brain metastasis in breast cancers, highlighting potential new targets for therapies. Researchers found that metabolically distinct cells have varying levels of glucose and glutamine usage, which can be targeted to reduce metastatic activity.
Researchers at Tufts University have found that manipulating voltage patterns in tumor cells can significantly reduce tumor cell invasion and metastasis in animal models. Using FDA-approved ion channel blockers, they were able to normalize cell voltages, decrease tumor growth, and limit the spread of cancer cells.
Researchers at Massachusetts General Hospital found that inhibiting the OR5B21 gene significantly decreased breast cancer metastasis to the brain, bones and lung. This discovery may lead to new therapeutic targets to prevent or delay breast cancer's spread.
Researchers have found that depleting copper levels in the body can greatly reduce the ability of cancer cells to metastasize, including aggressive breast cancer. The discovery provides hope for developing more effective treatments for high-risk triple-negative breast cancer.
Cancer cells secrete type III collagen to stay dormant, and when levels decrease, they wake up and create metastatic cancer. Researchers found that enriching the environment with collagen can force cells to remain in a dormant state and prevent tumor recurrence.
A recent UCLA-led study provided indirect evidence that PSMA PET/CT improves risk-stratification and prognostic capabilities for high-risk prostate cancer patients. The study found that PSMA nomogram outperformed existing tools in predicting clinical outcomes, suggesting its significance in disease course prediction.
Patients treated with pyrotinib plus capecitabine had a lower risk of death and longer progression-free survival compared to those receiving lapatinib plus capecitabine. Pyrotinib is an irreversible tyrosine kinase receptor inhibitor targeting HER2, EGFR, and HER4.
In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.
The study used multigene sequencing to identify genomic alterations in patients with metastatic breast cancer. Patients with genomic alterations ranked as ESCAT I/II saw improved progression-free survival with targeted therapies matched to their genomic changes, while those without these alterations did not benefit from the treatment.
A study published in eLife reveals that a small signalling protein called ARL4C is overexpressed in pancreatic cancer patients, facilitating their aggressive behavior. By inhibiting ARL4C, researchers have shown promise in reducing the spread of pancreatic cancer cells, opening up new therapeutic avenues.
Researchers found that tumor cells contribute differently to metastases and therapy resistance depending on their EMT status. Partial EMT breast cancer cells act as pioneer cells leading collective cell migration and promote lung metastases, while full EMT cells rarely appear in metastases.
Researchers at Princeton University have discovered a new compound that can disable the MTDH gene, which is essential for cancer progression and metastasis. The compound shows promise in treating major human cancers, including breast, prostate, lung, and colon cancers.
CNIO researchers have identified a new biomarker for early melanoma metastasis, proposing the use of NGFR to predict disease prognosis and define risk groups. Blocking NGFR drastically reduces metastasis in mice, paving the way for a potential first treatment to tackle metastasis in its earliest stages.
Researchers have discovered a new therapeutic approach that prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state. The drug C26 activates NR2F1, a protein that can induce cancer cell dormancy and prevent recurrence and metastasis.
A diet rich in palmitic acid makes tumor cells more aggressive and increases their metastatic capacity, a process that is responsible for 90% of cancer deaths. Exposure to palmitic acid leads to permanent epigenetic modifications in tumor cells, allowing them to conserve metastatic capacity even after the fatty acid is removed.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.
Research reveals that cancer cells have softer membranes than normal cells, but stiffening them can prevent abnormal changes in structure and motility. Stiffened breast cancer cells lost the ability to spread to the lungs in mouse experiments, suggesting a potential strategy for cancer treatments.
Children in UK and Ireland diagnosed with larger kidney cancers, leading to late diagnosis and potential poorer outcomes. A call for frontline healthcare workers to be trained in paediatric medicine has been made to improve early detection.
According to experts, half of patients with two common subtypes of advanced breast cancer may live for five years or longer. The new guidelines also aim to improve treatment options for triple-negative breast cancer patients.
A study found that arginine treatment improved outcomes in cancer patients with brain metastases, showing a complete or partial response in nearly 78% of patients. The amino acid may be useful as an anticancer therapy when combined with radiotherapy or other treatments.
A study published in Nature Communications found that neuroendocrine tumors in the small intestine often originate from different cells with unique genetic mutations. This breakthrough challenges conventional wisdom on cancer development and highlights the importance of removing all detected tumors to prevent late relapses.
A recent study published in PLOS ONE found that combining copper ions with a drug once used for treating alcoholism kills medulloblastoma cancer cells and prevents new ones from forming. The therapy also curtails the creation of cancer stem cells, which initiate tumor growth and recurrence.
A recent survey of advanced breast cancer patients in the UK reveals that only 14% have been recruited to a trial, highlighting a need for improved access. Patients often face barriers, including clinician reluctance to discuss trials and a lack of patient-friendly databases.
Researchers found that tumors with few micro-blood vessels are associated with defective perfusion, impacting the efficiency of systemic chemotherapy. This study highlights the importance of improving diagnostic imaging equipment to better detect lymph node metastasis and curb cancer-related mortality.
Researchers in mice found that chemotherapy enhances cancer's spread by making blood vessel walls more receptive, allowing cancer cells to latch on. The study shows how a chemo drug like cyclophosphamide alters non-cancer cells' properties, facilitating the cancer cells' attachment and progression.
A major global study found that the risk of breast cancer spreading to other parts of the body ranges from 6% to 22%. Younger women and those diagnosed with larger tumours face a higher risk. The study also sheds light on how many people develop advanced breast cancer, a gap in knowledge until now.
A new study finds that high-dose radiation therapy can lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted tumor growth or spread. Stereotactic body radiation therapy (SBRT) shows promise in treating oligoprogressive, metastatic lung and breast cancer.
A new, bacteria-based system can detect cancer cells and release therapeutic drugs directly into them, leaving healthy cells intact. The technology has shown promising results in preclinical tests on mice, particularly for liver cancer.
Researchers found that aggressive triple-negative breast cancer cells use swiprosin-1 to hijack a cellular conveyor belt, increasing integrin circulation and cell migration. High swiprosin-1 expression correlates with metastasis formation and malignancy in breast cancer.
Researchers from UPV/EHU and Biocruces pathologists use game theory to study tumor cell interactions, finding that higher cell diversity may be beneficial for patients. This approach reveals the importance of collective stability in tumor cells' pursuit of better environments.
Researchers at Sunnybrook Health Sciences Centre have successfully delivered antibody therapy to breast cancer metastases in the brain using focused ultrasound. The treatment, which temporarily opens the blood-brain barrier, has shown promising results with tumor size reductions of up to 21% in patients.
New research reveals that boosting numbers of immune cells called dendritic cells may be key to overcoming colorectal cancers' immunotherapy resistance. By augmenting dendritic cells in liver metastases, treatment led to increased cytotoxic T lymphocytes and made tumors sensitive to immune checkpoint inhibitors.
Researchers have discovered the molecular mechanisms behind stem cell rolling in blood vessels, a complex process that slows down cells using long tethers. The findings offer new insights into improving stem cell transplantations and developing treatments for metastasizing cancers.
A new study reveals a small molecule, RGX-202, that targets and prevents metastasis in colorectal cancer by blocking the uptake of phosphocreatine into cancer cells. The findings have led to a clinical trial in humans and may eventually increase survival rates for multiple gastrointestinal cancers.
A research team at TUM has discovered that the protein TIMP1 is associated with a significantly higher risk of liver metastasis and death in male patients, particularly those with pancreatic, colon, and melanoma cancers. This finding may lead to improved diagnosis and targeted therapy options for men.
Researchers discovered a combination of two drugs can reduce inflammation following chemotherapy, preventing metastasis in pancreatic and liver cancer. The treatment targets the sEH and EP4 pathways, modulating inflammation to resolve cytokine storms.
Researchers discovered that adrenal gland metastases are unresponsive to checkpoint inhibitors due to the secretion of corticosteroids. Surgical removal is the current best course of action for patients with these metastases. The study's authors hope to develop a nonsurgical treatment option in the future.
Researchers identified two subtypes of metastatic prostate cancer that respond differently to hormone treatment. Luminal tumors responded better to testosterone-blocking treatments, while basal tumors did not benefit as much from this hormone treatment.
Researchers analyzed data from over 3,200 brain metastatic tumors and discovered that different types of cancer tend to spread to specific parts of the brain. The study's findings may help predict where a particular cancer will metastasize and inform treatment strategies.
Researchers from FAU and MIT develop a microfluidic assay to study the mechanical performance of red blood cells under hypoxic conditions. The study reveals that cyclic hypoxia can lead to mechanical degradation of the red blood cell membrane, contributing to aging.
Scientists discovered a protein, IL13Ra2, that promotes brain metastases in breast cancer patients. High levels of this protein are associated with poor survival rates. Researchers aim to develop targeted therapies for this specific population.
Two phase III trials by VHIO researchers reveal significant clinical activity of trastuzumab deruxtecan in HER2-positive metastatic breast cancer, with over half of patients experiencing two years without disease progression. Trastuzumab duocarmazine also shows promise in treating HER2-negative breast cancer and other tumor types.
The MONALEESA-2 trial found that adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with HR-positive, HER2-negative advanced breast cancer. The combination of endocrine therapy and the CDK 4/6 inhibitor ribociclib also extends progression-free survival.
The KEYNOTE-826 study found that adding immunotherapy to standard first-line treatment increases overall survival by eight months for patients with recurrent, persistent or metastatic cervical cancer. The addition of pembrolizumab to chemotherapy also reduced the risk of death and disease progression by 33%.
Researchers developed a treatment using cowpea mosaic virus nanoparticles that target lung tumors, slowing tumor growth and preventing cancer spread. The treatment showed efficacy against aggressive cancer cell lines and may offer protection to patients at high risk of metastatic disease.
A novel population of long-lived T cells, called 'lymph node resident memory T cells,' provides protection against melanoma by persisting in lymph nodes. These cells were found to counteract melanoma spreading in mice and predicted better outcomes for human melanoma patients with lymph node metastases.
The Phase III POSEIDON trial demonstrated a statistically significant improvement in progression-free survival and overall survival for patients with metastatic non-small cell lung cancer (mNSCLC) treated with chemotherapy plus durvalumab and tremelimumab. Durvalumab combined with tremelimumab and chemotherapy reduced the risk of death...
The Vilcek Foundation has awarded four prizes worth $250,000 to foreign-born scientists in the United States. The prizes recognize outstanding career contributions to biomedical science and innovative research. This year's recipients include Vishva M. Dixit, Markita del Carpio Landry, Hani Goodarzi, and Harris Wang.
Research from Osaka City University reveals that hepatocellular carcinoma survival decreases as poorly differentiated tumor size increases. Tumors over 5cm have a significantly higher risk of early recurrence and spreading to other parts of the body.
Researchers identified a new growth factor produced by blood vessels that enables tumor cells to metastasize. The study, led by Hellmut Augustin, found that the production of LRG1 promotes the formation of a microenvironment that stimulates cancer cell growth and colonization.
A new combination treatment has shown significant tumor shrinkage and prolonged survival in patients with metastatic uveal melanoma. The treatment, which targets HDAC and PD-1 proteins, was found to work better in tumors with active BAP1 genes, a key discovery that may lead to improved survival rates.
A study in HNSC patients found that specific microRNAs, such as hsa-miR-203a-3p, mir-10a-5p, and miR-194-5p, are strongly associated with lymphovascular invasion (LVI). These miRNAs regulate biological pathways involved in tumor progression, making them potential prognostic indicators.